Journal Home
Search for

Volume 14, Issue 5, Pages 576-582 (May 2008)


View previous. 14 of 18 View next.

IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies

L. Lee Dupuis1234Corresponding Author Informationemail address, Cathryn Sibbald2, Tal Schechter3, Marc Ansari5, Adam Gassas3, Yves Théorêt68, Nastya Kassir9, Martin A. Champagne57, John Doyle34

Received 3 January 2008; accepted 6 March 2008.

Abstract 

We currently calculate area under the busulfan concentration time curve (AUC) using 7 plasma busulfan concentrations (AUC7) drawn after the first of 16 i.v. busulfan doses given as a 2-hour infusion every 6 hours. The aim of this study was to develop and validate limited sampling strategies (LSSs) using 3 or fewer busulfan concentration values with which to reliably calculate AUC in children undergoing hematopoietic stem cell transplant (HSCT). Children in the development group (44) received i.v. busulfan at Sick Kids; the validation group consisted of 35 children who received care at CHU Ste-Justine. Busulfan doses given and subsequent plasma busulfan concentrations were recorded. LSSs using 1 to 3 concentration-time points were developed using multiple linear regression. LSS were considered to be acceptable when adjusted r2 > 0.9, mean bias <15% and precision <15%. Extent of agreement between the AUC7 values and the LSS AUC was assessed by the intraclass correlation coefficient (ICC) and Bland-Altman (BA) analysis. Agreement was considered to be excellent when the lower limit of the 95% confidence limit of the ICC exceeded 0.9 and when the limits of agreement in the BA analysis were ±15% for both AUC and dose. Administration of the theoretic adjusted busulfan doses based on each LSS was simulated and cases where the resulting AUC was >1500 or <900 μM·min were noted. LSSs using 1, 2, or 3 plasma busulfan concentrations were developed that showed excellent agreement with AUC7 and adjusted busulfan doses. In the validation sample, only the 2- and 3-point LSSs demonstrated acceptable precision and lack of bias. LSSs using 2 or 3 plasma busulfan concentrations can be used to reliably estimate busulfan AUC after IV administration in children undergoing HSCT.

1 Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada

2 Department of Pharmacy, The Hospital for Sick Children, Toronto, Ontario, Canada

3 Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada

4 Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada

5 Division of Haematology/Oncology, CHU Ste-Justine, Montréal, Québec, Canada

6 Department of Clinical Biochemistry, CHU Ste-Justine, Montréal, Québec, Canada

7 Department of Pediatrics, Université de Montréal, Montréal, Québec, Canada

8 Department of Pharmacology, Université de Montréal, Montréal, Québec, Canada

9 Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada

Corresponding Author InformationCorrespondence and reprint requests: L.L. Dupuis, RPh., MScPhm., FCSHP, Department of Pharmacy, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.

PII: S1083-8791(08)00111-0

doi:10.1016/j.bbmt.2008.03.002


View previous. 14 of 18 View next.